Glioblastoma

Dual Antigen Targeting by CAR T Cells Improves Immunotherapeutic Technique

By

Chimeric antigen receptor (CAR) T cells may have improved therapeutic potential when they have 2 targets, according to preclinical findings using a mouse model.

Adding Temozolomide to Radiotherapy Improves Survival in Elderly Patients With Newly Diagnosed Glioblastoma

Adding Temozolomide to Radiotherapy Improves Survival in Elderly Patients With Newly Diagnosed Glioblastoma

By

The addition of temozolomide to standard short-course radiation therapy significantly improved both overall and progression-free survival in elderly patients with newly diagnosed glioblastoma, results from the first study to test this combination in this age group concluded in a plenary presentation at the ASCO 2016 Annual Meeting.

Personalized Medicine Approach Not Straightforward in Glioblastoma

Personalized Medicine Approach Not Straightforward in Glioblastoma

By

The role of antiangiogenic agents continues to evolve in the treatment of CNS cancers, attendees were told in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.

CDK4/6 Inhibitor Allows Sustained Dosing for Targeted Inhibition in 5 Solid Tumor Cancer Types

CDK4/6 Inhibitor Allows Sustained Dosing for Targeted Inhibition in 5 Solid Tumor Cancer Types

By

Abemaciclib, an investigational cancer therapeutic, showed durable clinical activity as a continuous single-agent therapy, according to results of a phase 1 trial with 5 tumor-specific cohorts.

Eight Immune Genes Identified As Playing a Role in Glioblastoma

Eight Immune Genes Identified As Playing a Role in Glioblastoma

Discovery might eventually lead to better treatment for glioblastoma multiforme

Phase 1 Study Results Show CAR T-cell Therapy Promising in Solid Brain Tumors

Phase 1 Study Results Show CAR T-cell Therapy Promising in Solid Brain Tumors

By

Glioblastoma tumors were successfully infiltrated by investigational CAR therapy with an acceptable safety profile.

Altered Metabolism of Four Compounds Drives Glioblastoma Growth

By

The altered metabolism of methionine, tryptophan, kynurenine, and 5-methylthioadenosine can drive the development of glioblastoma. Results also suggest ways to treat the cancer, slow its growth, and precisely elucidate its extent.

Bevacizumab Plus Irinotecan Improves PFS in MGMT-positive Glioblastoma

Bevacizumab Plus Irinotecan Improves PFS in MGMT-positive Glioblastoma

By

Bevacizumab plus irinotecan significantly improved the 6-month progression-free survival (PFS) rate and median progression-free survival.

Type of Electromagnetic Field Therapy Improves Survival for Patients With Brain Tumor

By

Progression-free and overall survival were prolonged with electromagnetic field and chemotherapy maintenance therapy in patients with a brain tumor.

Adding Tumor-treating Fields to Maintenance Therapy May Prolong Survival in Glioblastoma

Adding Tumor-treating Fields to Maintenance Therapy May Prolong Survival in Glioblastoma

By

Adding tumor-treating fields to maintenance temozolomide chemotherapy significantly prolonged progression-free survival.

Combination Regimen for Recurrent Glioblastoma Improves Progression-free Survival, But Not Overall Survival

By

Bevacizumab treatment combined with lomustine in patients with progressive glioblastoma, despite prolonged progression-free survival, does not confer a survival advantage.

Glioblastoma Stem Cells as a New Therapeutic Target for Glioblastoma

Glioblastoma Stem Cells as a New Therapeutic Target for Glioblastoma

[Clinical Medicine Insights: Oncology] This research examines hypoxia as a new therapeutic target for primary and secondary glioblastomas.

Peptide Reverses Temozolomide Resistance in Glioblastoma Cells

By

Scientists have discovered how to sensitize drug-resistant human glioblastoma cells to chemotherapy.

Liquid Biopsy of Cerebrospinal Fluid More Effective in Managing Brain Tumors

By

Liquid biopsy of cerebrospinal fluid has potential for prognosis, treatment, identification, and tracking of brain tumor genomic alterations both in real time and over time.

Gene Therapy Doubles Survival in Recurrent Glioblastoma

By

An experimental gene therapy essentially doubled the overall survival of patients with recurrent glioblastoma compared with the current standard of care.

Effects of glioblastoma treatments on healthy brain tissue continues after treatment is completed

By

The first study to examine the effects of combined radiation and chemotherapy on the healthy brain tissue of glioblastoma patients has revealed specific structural brain changes.

Technique disrupts glioblastoma tumor growth, improving survival in model

By

Hampering communication between cancer cells slowed the rapid spread of a common and deadly brain tumor significantly in a mouse model.

Epigenetic driver of glioblastoma provides new therapeutic target

By

Using human tumor samples and mouse models, researchers have found that cancer stem cell properties are determined by epigenetic changes.

Certain nutrients may fuel cancer therapy resistance

Certain nutrients may fuel cancer therapy resistance

By

Tumors can leverage glucose and acetate to resist targeted therapies directed at specific cellular molecules.

Drug treatment may benefit only select group of patients with glioblastoma

Drug treatment may benefit only select group of patients with glioblastoma

Clinicians testing dasatinib, approved for several blood cancers, were hoping to find that it would slow the growth of glioblastomas.

Nivolumab Demonstrates Consistent Adverse Event Profile for Recurrent Glioblastoma

Nivolumab Demonstrates Consistent Adverse Event Profile for Recurrent Glioblastoma

By

The adverse event profile of nivolumab with or without ipilimumab in patients with glioblastoma was encouraging.

New combination is a winning strategy against glioblastoma

By

A combination approach utilizing three differing anticancer drug classes could hold the key to besting glioblastoma.

Tetanus primer significantly improves survival after immunotherapy for glioblastoma

Tetanus primer significantly improves survival after immunotherapy for glioblastoma

An innovative pretreatment can enhance the effectiveness of immunotherapy for glioblastoma, dramatically improving patient survival.

What autism can teach us about brain cancer

By

Research into the transfer of proteins within the cells of patients with autism has helped broaden our understanding of brain cancer.

Three genes are tied to radiation resistance in recurrent glioblastoma tumors

By

A new study has identified three genes that combined enable a lethal form of brain cancer to recur and progress after radiation therapy.

Bevacizumab-induced hypertension is a marker for improved outcomes in recurrent glioblastoma

Bevacizumab-induced hypertension is a marker for improved outcomes in recurrent glioblastoma

Researchers have found that bevacizumab-induced hypertension may be a predictive marker of improved outcomes in patients with recurrent glioblastoma who are treated with bevacizumab.

Immune checkpoint inhibitors may work in brain cancers

By

New evidence indicates that immune checkpoint inhibitors may work in glioblastoma and brain metastases.

Drug targeting glioblastoma to begin clinical trial

By

A new drug breakthrough could extend the life of people living with glioblastoma, the most aggressive type of brain cancer.

Finding keys to drug therapy resistance in glioblastoma

Finding keys to drug therapy resistance in glioblastoma

By

Researchers have found one key as to why certain glioblastomas are resistant to drug therapy, and the answer lies in a tumor's epigenetic signature.

Triple therapy revs up immune system against a common brain tumor

By

A triple therapy for glioblastoma, consisting of two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs